|
|
Blood, 15 September 2005, Vol. 106, No. 6, pp. 2169-2174.
Prepublished online as a Blood First Edition Paper on June 2, 2005; DOI 10.1182/blood-2005-04-1565.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)
Pedro Farinha,
Hamid Masoudi,
Brian F. Skinnider,
Karey Shumansky,
John J. Spinelli,
Karamjit Gill,
Richard Klasa,
Nicolas Voss,
Joseph M. Connors, and
Randy D. Gascoyne
From the Department of Pathology, the Divisions of Medical Oncology and Radiation Oncology, and the Cancer Control Research Program, British Columbia Cancer Agency, Vancouver, BC; and the University of British Columbia and the Fraser Valley Cancer Clinic, Surrey, BC, Canada.
We studied the role of multiple biomarkers in determining outcome in follicular lymphoma (FL), concentrating in particular on the role of benign macrophages. The study group consisted of uniformly staged and treated patients with FL enrolled in a phase 2 trial between 1987 and 1993. All patients were younger than 61 years of age, had advanced-stage FL, and were treated with a multiagent chemotherapy regimen, BP-VACOP (bleomycin, cisplatin, etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone), followed by involved region radiation. The median follow-up of living patients was 12.5 years, and the median survival was 16.3 years. The International Prognostic Index (IPI) was predictive of overall survival (OS) (P = .003). Biopsy specimens from all cases were stained with an anti-CD68 antibody. Of the 99 evaluable patients with FL, 87 had less than 15 CD68+ macrophages/high-power field (hpf) (median, 7; range, 1-14) and 12 had more than 15 CD68+ macrophages/hpf (median, 20; range, 16-25) with a median OS of 16.3 vs 5.0 years, respectively (P < .001). A multivariate Cox model that included the IPI score, the histologic grade, and the lymphoma-associated macrophage (LAM) score, showed IPI and LAM to be independent predictors of OS (P = .009 and P = .004, respectively). The LAM content of FL predicts survival, and these data support a prominent role for nonneoplastic immune cells in the biology of FL. (Blood. 2005;106:2169-2174)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
N. A. Johnson and R. D. Gascoyne
Gene expression signatures in follicular lymphoma: are they ready for the clinic?
Haematologica,
July 1, 2008;
93(7):
982 - 987.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. P. Piccaluga, A. Califano, U. Klein, C. Agostinelli, B. Bellosillo, E. Gimeno, S. Serrano, F. Sole, Y. Zang, B. Falini, et al.
Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas
Haematologica,
July 1, 2008;
93(7):
1033 - 1038.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Kube, T.-D. Hua, F. von Bonin, N. Schoof, S. Zeynalova, M. Kloss, D. Gocht, B. Potthoff, M. Tzvetkov, J. Brockmoller, et al.
Effect of Interleukin-10 Gene Polymorphisms on Clinical Outcome of Patients with Aggressive Non-Hodgkin's Lymphoma: An Exploratory Study
Clin. Cancer Res.,
June 15, 2008;
14(12):
3777 - 3784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Dave
Follicular lymphoma and the microenvironment
Blood,
May 1, 2008;
111(9):
4427 - 4428.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Byers, E. Sakhinia, P. Joseph, C. Glennie, J. A. Hoyland, L. P. Menasce, J. A. Radford, and T. Illidge
Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling
Blood,
May 1, 2008;
111(9):
4764 - 4770.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Taskinen, M.-L. Karjalainen-Lindsberg, and S. Leppa
Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP
Blood,
May 1, 2008;
111(9):
4664 - 4667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Lee, I. Espinosa, S. Vrijaldenhoven, S. Subramanian, K. D. Montgomery, S. Zhu, R. J. Marinelli, J. L. Peterse, N. Poulin, T. O. Nielsen, et al.
Prognostic Significance of Macrophage Infiltration in Leiomyosarcomas
Clin. Cancer Res.,
March 1, 2008;
14(5):
1423 - 1430.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Canioni, G. Salles, N. Mounier, N. Brousse, M. Keuppens, F. Morchhauser, T. Lamy, A. Sonet, M.-C. Rousselet, C. Foussard, et al.
High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial
J. Clin. Oncol.,
January 20, 2008;
26(3):
440 - 446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Burkle, M. Niedermeier, A. Schmitt-Graff, W. G. Wierda, M. J. Keating, and J. A. Burger
Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia
Blood,
November 1, 2007;
110(9):
3316 - 3325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Taskinen, M.-L. Karjalainen-Lindsberg, H. Nyman, L.-M. Eerola, and S. Leppa
A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone
Clin. Cancer Res.,
October 1, 2007;
13(19):
5784 - 5789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. W. Ross, P. D. Ouillette, C. M. Saddler, K. A. Shedden, and S. N. Malek
Comprehensive Analysis of Copy Number and Allele Status Identifies Multiple Chromosome Defects Underlying Follicular Lymphoma Pathogenesis
Clin. Cancer Res.,
August 15, 2007;
13(16):
4777 - 4785.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Klapper, E. Hoster, L. Rolver, C. Schrader, D. Janssen, M. Tiemann, H.-W. Bernd, O. Determann, M.-L. Hansmann, P. Moller, et al.
Tumor Sclerosis but Not Cell Proliferation or Malignancy Grade Is a Prognostic Marker in Advanced-Stage Follicular Lymphoma: The German Low Grade Lymphoma Study Group
J. Clin. Oncol.,
August 1, 2007;
25(22):
3330 - 3336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Focosi and M. Petrini
CD57 Expression on Lymphoma Microenvironment As a New Prognostic Marker Related to Immune Dysfunction
J. Clin. Oncol.,
April 1, 2007;
25(10):
1289 - 1291.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Alvaro, M. Lejeune, M.-T. Salvado, C. Lopez, P. Escriva, J. Jaen, R. Bosch, and L. E. Pons
In Reply
J. Clin. Oncol.,
April 1, 2007;
25(10):
1291 - 1292.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Hilchey, A. De, L. M. Rimsza, R. B. Bankert, and S. H. Bernstein
Follicular Lymphoma Intratumoral CD4+CD25+GITR+ Regulatory T Cells Potently Suppress CD3/CD28-Costimulated Autologous and Allogeneic CD8+CD25- and CD4+CD25- T Cells
J. Immunol.,
April 1, 2007;
178(7):
4051 - 4061.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Glas, L. Knoops, L. Delahaye, M. J. Kersten, R. E. Kibbelaar, L. A. Wessels, R. van Laar, J. H. J.M. van Krieken, J. W. Baars, J. Raemaekers, et al.
Gene-Expression and Immunohistochemical Study of Specific T-Cell Subsets and Accessory Cell Types in the Transformation and Prognosis of Follicular Lymphoma
J. Clin. Oncol.,
February 1, 2007;
25(4):
390 - 398.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. E. Wahlin, B. Sander, B. Christensson, and E. Kimby
CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma
Clin. Cancer Res.,
January 15, 2007;
13(2):
388 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Salles
Clinical Features, Prognosis and Treatment of Follicular Lymphoma
Hematology,
January 1, 2007;
2007(1):
216 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Alvaro, M. Lejeune, M.-T. Salvado, C. Lopez, J. Jaen, R. Bosch, and L. E. Pons
Immunohistochemical Patterns of Reactive Microenvironment Are Associated With Clinicobiologic Behavior in Follicular Lymphoma Patients
J. Clin. Oncol.,
December 1, 2006;
24(34):
5350 - 5357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Canioni, G. Salles, N. Mounier, N. Brousse, M. Keuppens, F. Morchauser, M. Fournier, T. Lamy, M.-C. Rousselet, C. Foussard, et al.
The Poor Prognosis Value of High Intra-Tumoral Macrophages Counts in Follicular Lymphoma Patients Requires Selection of Appropriate Cut-Off and Can Be Circumvented by Rituximab Therapy.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
822 - 822.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. M. Lee, A. J. Clear, M. Calaminici, A. J. Davies, S. Jordan, F. MacDougall, J. Matthews, A. J. Norton, J. G. Gribben, T. A. Lister, et al.
Number of CD4+ Cells and Location of Forkhead Box Protein P3-Positive Cells in Diagnostic Follicular Lymphoma Tissue Microarrays Correlates With Outcome
J. Clin. Oncol.,
November 1, 2006;
24(31):
5052 - 5059.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Carreras, A. Lopez-Guillermo, B. C. Fox, L. Colomo, A. Martinez, G. Roncador, E. Montserrat, E. Campo, and A. H. Banham
High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma
Blood,
November 1, 2006;
108(9):
2957 - 2964.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Ruan, E. Hyjek, P. Kermani, P. J. Christos, A. T. Hooper, M. Coleman, B. Hempstead, J. P. Leonard, A. Chadburn, and S. Rafii
Magnitude of Stromal Hemangiogenesis Correlates with Histologic Subtype of Non-Hodgkin's Lymphoma.
Clin. Cancer Res.,
October 1, 2006;
12(19):
5622 - 5631.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Lewis and J. W. Pollard
Distinct Role of Macrophages in Different Tumor Microenvironments
Cancer Res.,
January 15, 2006;
66(2):
605 - 612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. H. Sehn
Optimal Use of Prognostic Factors in Non-Hodgkin Lymphoma
Hematology,
January 1, 2006;
2006(1):
295 - 302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Gascoyne
Hematopathology Approaches to Diagnosis and Prognosis of Indolent B-Cell Lymphomas
Hematology,
January 1, 2005;
2005(1):
299 - 306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Freedman
Biology and Management of Histologic Transformation of Indolent Lymphoma
Hematology,
January 1, 2005;
2005(1):
314 - 320.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
